Actually it's 75% of those who had reduced or low levels of CTCs that make up that 3600% number. 25% who had reduced or low levels of CTCs are not included in that number. My best guess is that most of the 25% were in extremely late stages of cancer and it may have been to late for leronlimab to turn them around.

Quote:

---

75% of the patients who exhibited a lower level of circulating cells after leronlimab (86%) or at baseline (14%) exhibited a 3600% increase in 12-month Overall Survival (“OS”) (p = 0.0004),

---